Physician profile
Ralph D Wade
NPI 1447256953
$4,733.32
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $1,908 · 2020: $1,373 · 2021: $1,440 · 2022: $12.30.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $614.74 | 2019-2021 | |
| Novo Nordisk INC | $498.95 | 2019-2021 | |
| Abbvie INC. | $457.53 | 2019-2022 | |
| Amarin Pharma, INC. | $436.81 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $429.56 | 2019-2021 | |
| Merz North America, INC. | $268.85 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $255.34 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.72 | 2019-2021 | |
| Lilly USA, LLC | $194.28 | 2019-2021 | |
| Boston Scientific Corporation | $171.35 | 2019-2021 | |
| Astellas Pharma US INC | $153.19 | 2019-2021 | |
| Allergan, INC. | $132.00 | 2019-2020 | |
| Glaxosmithkline, LLC. | $123.96 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $108.93 | 2021 | |
| Janssen Pharmaceuticals, INC | $86.36 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $85.83 | 2020-2021 | |
| Pfizer INC. | $68.25 | 2019-2021 | |
| Amgen INC. | $67.49 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $59.40 | 2020-2021 | |
| Eisai INC. | $39.78 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $39.09 | 2019-2021 | |
| Cranial Technologies, INC | $29.27 | 2020-2021 | |
| Fidia Pharma USA INC. | $28.08 | 2019 | |
| Adlon Therapeutics L.P. | $25.23 | 2020-2021 | |
| Nalpropion Pharmaceuticals LLC | $24.72 | 2019 | |
| Ironshore Pharmaceuticals INC. | $23.56 | 2019 | |
| Jazz Pharmaceuticals INC. | $16.23 | 2021 | |
| Tandem Diabetes Care, INC. | $14.09 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.62 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.51 | 2021 | |
| Janssen Biotech, INC. | $13.38 | 2019 | |
| Circassia INC. | $12.12 | 2019 | |
| Medtronic, INC. | $11.58 | 2021 | |
| Corcept Therapeutics | $11.52 | 2020 |
6 companies reported research payments only; those appear in the research section below.
Research and ownership
$1,164.72 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Wade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.